Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yehuda E Deutsch

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Leukemia & Lymphoma|May 31, 2011
CD30: an important new target in hematologic malignanciesYehuda E Deutsch, Tamar Tadmor, Eckhard R Podack, et al.
Case Reports in Oncology|April 22, 2016
Stewart-Treves Syndrome: A Case Report and Review of the LiteratureRoberto Berebichez-Fridman, Yehuda E Deutsch, Thomas M Joyal, et al.
Cancer|September 15, 2022
Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutationsSomedeb Ball, Todd C Knepper, Yehuda E Deutsch, et al.
American Journal of Hematology|January 4, 2022
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitorsYazan Numan, Zaid Abdel Rahman, Justin Grenet, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Leukemia & Lymphoma|May 31, 2011
CD30: an important new target in hematologic malignanciesYehuda E Deutsch, Tamar Tadmor, Eckhard R Podack, et al.
Case Reports in Oncology|April 22, 2016
Stewart-Treves Syndrome: A Case Report and Review of the LiteratureRoberto Berebichez-Fridman, Yehuda E Deutsch, Thomas M Joyal, et al.
Cancer|September 15, 2022
Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutationsSomedeb Ball, Todd C Knepper, Yehuda E Deutsch, et al.
American Journal of Hematology|January 4, 2022
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitorsYazan Numan, Zaid Abdel Rahman, Justin Grenet, et al.
Pageof 1